Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 29 peer-reviewed journal articles Updated
Neurology

Diagnosing CMD and Finding Your Subtype

At a Glance

Whole Exome Sequencing (WES) is the gold standard for diagnosing Congenital Muscular Dystrophy (CMD). Identifying your child's exact genetic subtype is crucial, as it dictates their specific screening needs for heart, breathing, and neurological risks.

Finding the exact “name” for your child’s condition is the most important step in their care. Because Congenital Muscular Dystrophy (CMD) is an umbrella term, doctors use a combination of blood tests, imaging, and advanced genetics to identify the specific subtype [1][2].

The Gold Standard: Genetic Testing

Today, Whole Exome Sequencing (WES) is considered the first-line diagnostic tool for CMD [3][4]. This test “reads” the protein-coding sections of your child’s DNA to find the specific mutation causing the muscle weakness. This often ends the “diagnostic odyssey” and provides a clear roadmap for what to expect [5][6].

Because CMDs are genetic conditions, getting a WES diagnosis has implications beyond your child. It is highly recommended that parents meet with a Genetic Counselor after receiving the results. A counselor can help you understand your own carrier status and the recurrence risk if you choose to have more children.

The CK Level: A Vital Clue

A common first step is a blood test for Creatine Kinase (CK). CK is an enzyme that leaks out of muscles when they are damaged. While not a diagnosis on its own, the level can point doctors toward certain subtypes [7][8]:

CK Level Typical Range Likely Subtypes
Very High >1,000 to 10,000+ IU/L LAMA2-RD, Dystroglycanopathies [9][10]
Moderate 500 to 1,000 IU/L LMNA-RD (can be normal) [11]
Normal / Mild <500 IU/L COL6-RD, SELENON (SEPN1)-RD [12][13]

The “Big Five” Subtypes

Understanding which gene is affected helps you prepare for your child’s specific needs:

  1. LAMA2-Related (Merosin Deficient): Characterized by very high CK and distinct white matter changes on brain MRI [14][15]. Most children have normal intelligence, but parents should be aware that this specific change in the brain carries a notable risk for seizures (epilepsy) [14][16].
  2. COL6-Related (Ullrich/Bethlem): Notable for “double-jointed” fingers and toes but stiffening (contractures) in the elbows and knees [17]. CK is often normal or only slightly high [12].
  3. Dystroglycanopathies (WWS, MEB, FCMD): This group often involves both the muscles and the brain/eyes [18]. Walker-Warburg Syndrome (WWS) is the most severe form, while others like Fukuyama (FCMD) may be more moderate [19][20].
  4. LMNA-Related (Laminopathy): Often presents with “dropped head” syndrome (neck weakness) and carries a significant risk for heart rhythm problems (arrhythmias) that require close monitoring [21][22].
  5. SELENON-Related (formerly SEPN1): Known for causing Rigid Spine Syndrome, where the back and neck become very stiff [23]. The biggest risk here is early-onset breathing weakness, especially at night [24][25].

Other Diagnostic Tools

While genetics is primary, other tests provide “pieces of the puzzle”:

  • Muscle MRI: Shows specific patterns of “fatty infiltration” (where fat replaces muscle) that are unique to different subtypes [26][27].
  • Brain MRI: Crucial for identifying the structural changes seen in LAMA2-RD or Dystroglycanopathies [14][28].
  • Muscle Biopsy: If genetic testing is unclear, a small piece of muscle is examined. The pathology report will look for missing proteins (like “merosin” or “collagen VI”) or signs of “dystrophic changes” (muscle breakdown and scarring) [29][17].

Diagnostic Completeness Checklist

  • [ ] Blood test for CK levels
  • [ ] Whole Exome Sequencing (WES) or a comprehensive CMD genetic panel
  • [ ] Meeting with a Genetic Counselor to discuss results
  • [ ] Brain MRI (especially if LAMA2 or a Dystroglycanopathy is suspected)
  • [ ] Referral to a Neuromuscular Specialist
  • [ ] Heart screening (EKG/Echo) and Baseline Breathing Test (Spirometry) if a specific subtype is found

Common questions in this guide

What is the best test for diagnosing Congenital Muscular Dystrophy?
Whole Exome Sequencing (WES) is considered the gold standard for diagnosing CMD. It analyzes the protein-coding sections of your child's DNA to identify the exact genetic mutation causing their muscle weakness.
Why do doctors check my child's CK (creatine kinase) levels?
Creatine kinase is an enzyme that leaks into the blood when muscles are damaged. While high CK levels do not provide a final diagnosis, they give doctors vital clues to narrow down which CMD subtype your child might have.
What does it mean if my child's brain MRI shows white matter changes?
White matter changes on a brain MRI are a distinct diagnostic clue often seen in LAMA2-related CMD. This finding helps doctors pinpoint the subtype and indicates a need to monitor for an increased risk of seizures.
Why is finding the exact CMD subtype so important?
Finding the exact genetic subtype provides a clear roadmap for your child's care. Different subtypes carry unique risks, such as heart rhythm problems, nighttime breathing weakness, or seizures, which require specialized monitoring.
What happens if genetic testing doesn't confirm a CMD subtype?
If genetic testing is inconclusive or finds a variant of uncertain significance, doctors may recommend a muscle biopsy. The pathology report from the biopsy can look for missing proteins or signs of muscle breakdown to help confirm the diagnosis.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my child's CK levels, which specific subtypes are most likely, and has the genetic panel covered all of them?
  2. 2.Was the genetic testing performed a broad Whole Exome Sequencing (WES) or a more limited neuromuscular panel?
  3. 3.What did the brain MRI show regarding white matter or brain structure, and how does that narrow down the diagnosis?
  4. 4.Does my child's subtype require immediate screening for heart rhythm issues (arrhythmias) or nighttime breathing (sleep study)?
  5. 5.If the genetic testing was 'inconclusive' or found a 'Variant of Uncertain Significance' (VUS), should we consider a muscle biopsy to confirm the protein levels?
  6. 6.Can you refer us to a genetic counselor to discuss these WES results and what they mean for our family planning?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (29)
  1. 1

    Compound heterozygous POMGNT1 mutations leading to muscular dystrophy-dystroglycanopathy type A3: a case report.

    Borisovna KO, Yurievna KA, Yurievich TK, et al.

    BMC pediatrics 2019; (19(1)):98 doi:10.1186/s12887-019-1470-2.

    PMID: 30961548
  2. 2

    Broadening the paradigm of laminin α2-related muscular dystrophy: A case of partial merosin deficiency with compound heterozygous variants.

    Tavasoli A, Eghdami S, Kachuei M, Rouzbeh S

    SAGE open medical case reports 2025; (13()):2050313X251366020 doi:10.1177/2050313X251366020.

    PMID: 40874012
  3. 3

    Genetic blueprint of congenital muscular dystrophies with brain malformations in Egypt: A report of 11 families.

    Safwat S, Flannery KP, El Beheiry AA, et al.

    Neurogenetics 2024; (25(2)):93-102 doi:10.1007/s10048-024-00745-z.

    PMID: 38296890
  4. 4

    Congenital muscle dystrophies: Role of singleton whole exome sequencing in countries with limited resources.

    Masri AT, Oweis L, Qudah AA, El-Shanti H

    Clinical neurology and neurosurgery 2022; (217()):107271 doi:10.1016/j.clineuro.2022.107271.

    PMID: 35533453
  5. 5

    [Exome diagnostics in neurology].

    Zech M, Wagner M, Schormair B, et al.

    Der Nervenarzt 2019; (90(2)):131-137 doi:10.1007/s00115-018-0667-1.

    PMID: 30645660
  6. 6

    Identification of a compound heterozygous missense mutation in LAMA2 gene from a patient with merosin-deficient congenital muscular dystrophy type 1A.

    Khorrami A, Goleij P, Karamad V, et al.

    Journal of clinical laboratory analysis 2021; (35(11)):e23930 doi:10.1002/jcla.23930.

    PMID: 34528292
  7. 7

    Identifying Non-Duchenne Muscular Dystrophy-Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review.

    Gatheridge MA, Kwon JM, Mendell JM, et al.

    JAMA neurology 2016; (73(1)):111-6 doi:10.1001/jamaneurol.2015.3537.

    PMID: 26594870
  8. 8

    LAMA2 variants associated with muscular dystrophy, brain structural abnormalities, and epilepsy: a genotype-phenotype study.

    Zha J, Yu Y, Cao F, et al.

    Frontiers in neurology 2025; (16()):1728652 doi:10.3389/fneur.2025.1728652.

    PMID: 41567540
  9. 9

    LAMA2-Related Dystrophies: Clinical Phenotypes, Disease Biomarkers, and Clinical Trial Readiness.

    Sarkozy A, Foley AR, Zambon AA, et al.

    Frontiers in molecular neuroscience 2020; (13()):123 doi:10.3389/fnmol.2020.00123.

    PMID: 32848593
  10. 10

    POMT1 and POMT2 gene mutations result in 2 cases of alpha-dystroglycanopathy.

    Gan S, Yang H, Xiao T, et al.

    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2021; (46(8)):915-919 doi:10.11817/j.issn.1672-7347.2021.200067.

    PMID: 34565739
  11. 11

    [A case of laminopathy with the mutation of LMNA gene identified by the exome analysis of disease-related genes].

    Nakamura K, Matsuda T, Hanaoka T, et al.

    Rinsho shinkeigaku = Clinical neurology 2021; (61(10)):663-670 doi:10.5692/clinicalneurol.cn-001610.

    PMID: 34565751
  12. 12

    Clinical, Pathologic, and Genetic Spectrum of Collagen VI-Related Disorder in China-A Retrospective Observational Multicenter Study.

    Hu C, Shi Y, Zhao L, et al.

    Human mutation 2024; (2024()):3503253 doi:10.1155/2024/3503253.

    PMID: 40225934
  13. 13

    Novel SEPN1 Mutations in Exon 1 Are Common in Rigid Spine With Muscular Dystrophy Type 1 in Chinese Patients.

    Fan Y, Xu Z, Li X, et al.

    Frontiers in genetics 2022; (13()):825793 doi:10.3389/fgene.2022.825793.

    PMID: 35368679
  14. 14

    Novel LAMA2 variants identified in a patient with white matter abnormalities.

    Yamamoto-Shimojima K, Ono H, Imaizumi T, Yamamoto T

    Human genome variation 2020; (7()):16 doi:10.1038/s41439-020-0103-5.

    PMID: 32509318
  15. 15

    Merosin-negative congenital muscular dystrophy: Report of five cases.

    Incecik F, Herguner OM, Ceylaner S, Altunbasak S

    Journal of pediatric neurosciences 2015; (10(4)):346-9 doi:10.4103/1817-1745.174432.

    PMID: 26962340
  16. 16

    Occipital cortex dysgenesis with white matter changes due to mutations in Laminin a2.

    Yiş U, Dixit V, Işıkay S, et al.

    The Turkish journal of pediatrics 2017; (59(3)):338-341.

    PMID: 29376585
  17. 17

    Skin Biopsy for Diagnosis of Ullrich Congenital Muscular Dystrophy: An Observational Study.

    Chakrabarty B, Sharma MC, Gulati S, Sarkar C

    Journal of child neurology 2017; (32(14)):1099-1103 doi:10.1177/0883073817738466.

    PMID: 29129153
  18. 18

    Mechanistic aspects of the formation of α-dystroglycan and therapeutic research for the treatment of α-dystroglycanopathy: A review.

    Taniguchi-Ikeda M, Morioka I, Iijima K, Toda T

    Molecular aspects of medicine 2016; (51()):115-24.

    PMID: 27421908
  19. 19

    Characteristic Cochlear Hypoplasia in Patients with Walker-Warburg Syndrome: A Radiologic Study of the Inner Ear in α-Dystroglycan-Related Muscular Disorders.

    Talenti G, Robson C, Severino MS, et al.

    AJNR. American journal of neuroradiology 2021; (42(1)):167-172 doi:10.3174/ajnr.A6858.

    PMID: 33122211
  20. 20

    Expanding the Phenotype of B3GALNT2-Related Disorders.

    D'haenens E, Vergult S, Menten B, et al.

    Genes 2022; (13(4)) doi:10.3390/genes13040694.

    PMID: 35456500
  21. 21

    International retrospective natural history study of LMNA-related congenital muscular dystrophy.

    Ben Yaou R, Yun P, Dabaj I, et al.

    Brain communications 2021; (3(3)):fcab075 doi:10.1093/braincomms/fcab075.

    PMID: 34240052
  22. 22

    Congenital LMNA-Related Muscular Dystrophy in Paediatrics: Cardiac Management in Monozygotic Twins.

    Martínez Olorón P, Alegría I, Cesar S, et al.

    International journal of molecular sciences 2024; (25(11)) doi:10.3390/ijms25115836.

    PMID: 38892025
  23. 23

    A novel mutation in SEPN1 causing rigid spine muscular dystrophy 1: a Case report.

    Ziyaee F, Shorafa E, Dastsooz H, et al.

    BMC medical genetics 2019; (20(1)):13 doi:10.1186/s12881-018-0743-1.

    PMID: 30642275
  24. 24

    Targeted next generation sequencing identifies two novel mutations in SEPN1 in rigid spine muscular dystrophy 1.

    Dai Y, Liang S, Huang Y, et al.

    Oncotarget 2016; (7(51)):83843-83849 doi:10.18632/oncotarget.13337.

    PMID: 27863379
  25. 25

    The clinical, histologic, and genotypic spectrum of SEPN1-related myopathy: A case series.

    Villar-Quiles RN, von der Hagen M, Métay C, et al.

    Neurology 2020; (95(11)):e1512-e1527 doi:10.1212/WNL.0000000000010327.

    PMID: 32796131
  26. 26

    Whole-body muscle MRI characteristics of LAMA2-related congenital muscular dystrophy children: An emerging pattern.

    Sakr HM, Fahmy N, Elsayed NS, et al.

    Neuromuscular disorders : NMD 2021; (31(9)):814-823 doi:10.1016/j.nmd.2021.06.012.

    PMID: 34481707
  27. 27

    Muscle Magnetic Resonance Imaging in Patients with Various Clinical Subtypes of LMNA-Related Muscular Dystrophy.

    Lin HT, Liu X, Zhang W, et al.

    Chinese medical journal 2018; (131(12)):1472-1479 doi:10.4103/0366-6999.233957.

    PMID: 29893365
  28. 28

    LAMA2-Related Muscular Dystrophy: The Importance of Accurate Phenotyping and Brain Imaging in the Diagnosis of LGMD.

    Stojkovic T, Masingue M, Métay C, et al.

    Journal of neuromuscular diseases 2023; (10(1)):125-133 doi:10.3233/JND-221555.

    PMID: 36373293
  29. 29

    Merosin-deficient congenital muscular dystrophy: A novel homozygous mutation in the laminin-2 gene.

    Turner C, Mein R, Sharpe C, Love DR

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2015; (22(12)):1983-5.

    PMID: 26249246

This page provides educational information about diagnosing Congenital Muscular Dystrophy (CMD) and identifying genetic subtypes. Always consult your pediatric neurologist or genetic counselor to interpret your child's specific test results.

Get notified when new evidence is published on Congenital muscular dystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.